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1. Introduction
Hepatic veno-occlusive disease (HVOD): was described as a non portal cirrhosis occurring
frequently in children and occasionally in adults. Now it is considered an important cause of
non cirrhotic portal hypertension particularly in children [1].
Rollins 1989 [2], stated that HVOD is a non-thrombotic obliteration of small intrahepatic
veins by loose connective tissues. The venous occlusion may be progressive and lead to mas‐
sive hepatocellular necrosis. However the precise pathogenesis is still obscure but also most
likely relates to venous endothelial injury.
Originally the syndrome was described in South Africa at 1920, but at present it is endemic
in Jamaica, encountered in Afghanistan and India. The syndrome was described under dif‐
ferent names, from Jamaica the disease was described under the term Jamaican veno-occlu‐
sive disease, in India the disease was given the term Indian childhood Cirrhosis (ICC), in
Europe HVOD has been called endophlebitis obliterans of which sporadic cases were descri‐
bed, as in Germany. Hepatic veno- occlusive disease was examined by scanning electron mi‐
croscopy (SEM). SEM correlated its histology and postmortem examination and disclosed
microscopic occlusion of the centrilobular and sublobular veins in the liver, these veins were
occluded partially or completely by intimal and medial thickening of their walls due to pro‐
liferation of collagen and reticulin fibers. In addition to venous obliteration, which had not
been demonstrated by other techniques, frequent occlusion of the sinusoidal opening into
the central veins was observed by SEM. [4], [5], [6].
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Hepatic veno-occlusive disease has been recognized as being due to the toxic effects of some
remedies, recently pyrrolizidine alkaloids mostly involved, as in senecio (bush teas) and cro‐
talaria (comfrey trees). It is also now seen as complication of high dose of anti-neoplastic
chemotherapy, especially in the setting of bone marrow transplantation. HVOD may be
familial, so the term “veno occlusive familial hepatic disease” [7], [8], [9].
2. Hepatic veno-occlusive disease (HVOD) in Egypt: Overview
In Egypt Hashem 1939 [7], gave the first reference to this syndrome, in his study of portal
cirrhosis among Egyptian children. Since 1939 several reports pointed out the occurrence of
a specific syndrome among Egyptian children who rapidly developed abdominal distention
with ascites and hepatomegaly. In 1965, Safouh et al [11]; reported that 54 Egyptian children
were studied and the term "Hepatic vein occlusion disease in Egyptian children" was ap‐
plied. At the same year, El Gholmy 1956 [10], studied a group of patients and introduced the
term “Infantile cirrhosis of Egypt”
The different reports from Egypt, thereafter, describing the syndrome, the clinical picture,
the pathology and the etiology revealed that HVOD is not uncommon among Egyptian in‐
fants and young children. They also have shown clearly for the first time that hepatic vein
occlusion should be considered in the diagnosis of Egyptian children presenting with hepa‐
tosplenomegaly [11].
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Safouh 1965 [11], reported that the Egyptian hepatic vein occlusion is the result of enhanced
thrombotic activity of the blood with the formation of fibrinous thrombi followed by organi‐
zation and thickening or closure of the vessels, a finding which seems peculiar to the Egyp‐
tian cases and thus differs from the classical HVOD.
3. Clinical Picture of HVOD
Clinical diagnosis is based on; hepatomegaly and/or right upper quadrant pain, ascites or
unexplained weight gain and also jaundice may or may not present [7].
The acute stage starts abruptly with abdominal discomfort or pain accompanied by hepato‐
megaly and ascites, nausea and vomiting are common. Histologically the liver shows an
edematous endophlebitis of the central veins associated with centrilobular congestion, hem‐
orrhage and necrosis. Mclean 1969 [12], has shown experimentally that the block occurs first
at the outlets of the sinusoids. Patients surviving the acute stage may progress to the suba‐
cute stage with persistent hepatomegaly and ascites which then diminish if an adequate col‐




Mild continuous dragging pain in right hypochondrium
Anorexia, nausea and vomiting
Rapidly filling ascites
Distended veins over the abdomin
Oliguria and pedal edema
Hepatomegaly
Splenomegaly in some cases
Tandon 1977
4. Diagnosis of HVOD
In the acute phase the diagnosis is usually readily made from the history and the character‐
istic clinical picture. In the sub-acute and chronic stages the diagnosis may be more difficult.
In all stages the diagnosis is confirmed by the characteristic histopathological findings of liv‐
er biopsy in the absence of extrahepatic venous obstruction.




1. Safouh et al; 1965 [11] reported the following results:
# Most of the cases showed some degree of anemia.
# Total and differential leukocytic counts did not show any constant deviation from normal.
# Liver function tests showed that : * Serum bilirubin was always below 3 mg/dl, * Serum
AST varied between 20 and 60 units, * Serum ALT and alkaline phosphatase were found to
be normal.
# Erythrocyte sedimentation rate ( ESR ) was low in spite of advanced state of the disease.
# The pattern of serum total proteins showed a state of hypoproteinemia ranging from 4-5
gm/dl and the albumen fraction is usually is decreased but globulin fraction may be in‐
creased.
2. Millis and Bale 1976 [13], stated that a feature of their cases is the partial immune deficien‐
cy. However, such a state of hypogammaglobulinemia reported by them goes parallel with
findings in the acute cases only, that their cases were quite a different group of patients suf‐
fering from genetic immunodeficiency as observed from the very early appearance of the
syndrome in some of them being as early as days.
3. Serum procollagen type III is an early and sensitive marker in VOD after BM transplanta‐
tion, usually above 100 ng /ml.
4. Serum protein S,C, liedin factor
4.2. Ultrasonographic scaning of the liver:
It is of definite help in the diagnosis of this syndrome, it showed that the liver is enlarged es‐
pecially the caudate lobe, splenic enlargement is usually of mild degree and ascites is always
found in acute cases. Narrowing of inferior vena cava could be detected in 40% of cases. Ex‐
amination of the terminal parts of the hepatic veins demonstrated their occlusion or attenua‐
tion, a finding which is considered a new and significant contribution to the early diagnosis
of this syndrome [14].
4.3. Inferior vena cava angiogram:
Presented as narrow or closed intra-hepatic portion of the inferior vena cava with marked
collaterals [14].
4.4. Liver biopsy:
In the acute stage it shows centrilobular hemorrhage, necrosis and sinusoidal dilatation. In
the chronic stage it presents picture of micronodular cirrhosis with normal portal tracts [7].
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4.5. Other tools of investigations [14]
• The ascitic fluid is a main laboratory field of investigations. It usually shows protein val‐
ues ranging between 1-3.5 gms/dl with occasional lymphocytes.
• Other sophisticated modules of investigations might be carried out : liver isotopic scan‐
ning, splenoportal venogram and arterio-venography of the portal system.
5. Management of Hepatic veno-occlusive disease:
No effective therapy until now especially in this type of Egyptian children. The target of available
line is, may be, to reduce the complications, to reduce the stress of the patients and keep the
patients in nearly comfortable life, but the following measures could be used safely [14].
5.1. Preventive measures:
• More investigation for the etiology of the disease especially pyrrolizidine alkaloids.
• Encouraging the breast feeding for two years as Glorious Qura’n says. (Sorra El bakara ),
regulation and careful inspection of diet after weaning [11].
• Good nutrition of the mother
• What about copper utensils ?? it suspected to play a role in indian cirrhosis !
5.2. Conservative measures :
• Follow up, because a grossly abnormal scan of liver and spleen in a patient with HVOD
has been normalized completely without any interference.
• Colonic lavage to wash out the toxic metabolites.
5.3. Medical treatment:
• Low doses of heparin or anticoagulants, adapted dose of prostacyclin.
• Anti inflammatory or steroids.
• Use of Vit C, use of Vit. E and Glutamine (source of glutathione) as antioxidants [15].
• Use of recombinant tissue plasminogen activator (rtPA), especially in patients after BM trans‐
plantation, Urokinase especially in cases with bleeding diathesis leading to thrombotic
HVOD [15], [16], [17].
• Diuretics for ascites.
• Large doses of glucose together with insulin to aid glycogen deposition in the liver and so
help its nutrition.
• Cupper chelation treatment (Di-penecillamine)
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5.4. Surgical treatment [18].
5.4.1. Treatment of ascites :
• Frequent aspiration (partial or full)
• TIPS ( transjagular intrahepatic portosystemic shunt)
• Hepatic and portal decompression for interactable ascites.
• LeVeen, peritoneojagular shunt.
5.4.2. Treatment of portal hypertension:
• Porto-systemic shunt as porto-caval, spleno-renal or meso-atrial.
• Acute venous obstruction could be treated by hepatofugal portal flow via veno-venous
bypass to drain arterial blood flow.
5.4.3. Liver transplantation:
• It is now a part of the therapeutic armamentarium for this condition.
6. Therapeutic paracentesis [21].
The first study re-evaluating paracentesis as a treatment of cirrhotic patients with ascites
consisted of a randomized controlled trial comparing repeated large-volume paracentesis
(4-6 l/day until the disappearance of ascites) plus intravenous albumin infusion (40g after
each tap) with standard diuretic therapy (frusemide plus spironolactone) in I17 patients
with tense ascites and avid sodium retention who were admitted to several hospitals in the
Barcelona area. This study, later confirmed by two more trials performed in Milan and Bar‐
celona, showed the following results:
1. paracentesis was more effective than diuretics in eliminating ascites (96.5 versus 72.8%);
2. paracentesis plus albumin infusion did not induce significant changes in hepatic and renal
function, serum electrolytes, cardiac output, plasma volume, plasma renin activity and plas‐
ma concentration of noradrenaline and antidiuretic hormone.
3. the incidence of hyponatremia, hepatic encephalopathy and renal impairment was much
lower in patients treated with paracentesis.
4. the duration of hospital stay was lower in patients treated with paracentesis.
5. there were no significant probability of re-admission, probability of survival and causes of
death between the two groups of patients.
Tito et al., later investigated whether ascites can be safely mobilized by total paracentesis
(complete removal of ascites by a single paracentesis) plus intravenous albumin infusion
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(6-8 g/l removed) in a one day hospitalization regime. The incidence of complications and
the clinical course of the disease, as estimated by the probability of readmission to hospital,
causes of re-admission, probability of survival and causes of death, were comparable to
those reported by the same group of investigators in patients treated with repeated large-
volume paracentesis.
In conclusion, these studies demonstrate that mobilization of ascites by paracentesis associat‐
ed with intravenous albumin infusion does not impair systemic haemodynamics and renal
function in patients with cirrhosis and tense ascites. Therapeutic paracentesis should be the
treatment of choice for cirrhotic patients admitted to hospital with tense ascites, because it is
more effective in mobilizing associated with a lower incidence of complications and reduce the
duration of hospitalization. To avoid re-accumulation of ascites, patients treated with paracent‐
esis require dietary sodium restriction and administration of diuretics after the procedures.
Subsequently, a trial was performed to establish whether intravenous albumin infusion is
necessary in cirrhotic patients with tense ascites treated with repeated large-volume para‐
centesis. It was observed that paracentesis plus intravenous albumin does not induce signifi‐
cant changes in standard renal function testes, plasma renin activity and plasma aldosterone
concentration. In contrast, paracentesis without albumin was associated with a significant
increase in blood urea nitrogen, a marked elevation in plasma renin activity and plasma al‐
dosterone concentration, and a significant reduction in serum sodium concentration. The
number of patients developing hyponatremia and renal impairment was remarkably higher
in patients treated with repeated large-volume paracentesis without intravenous albumin
infusion. There are two detailed investigations assessing the effects of large-volume para‐
centesis without albumin infusion on systemic haemodynamics vasoactive hormones and
renal function. A significant increase in cardiac output was observed 1 hour after treatment
in both studies. Some hours later, however, a significant drop below baseline values was ob‐
served in cardiac output, pulmonary wedge capillary pressure and central venous pressure.
Plasma renin activity increased and plasma atrial natriuretic peptide concentration de‐
creased. The adverse effects observed after complete mobilization of ascites by paracentesis
without albumin expansion did not occur in patients in whom ascites was only partially mo‐
bilized by paracentesis without colloid replacement. In conclusion, these studies demon‐
strate that complete mobilization of ascites by paracentesis without plasma volume
expansion is followed by a reduction in effective intravascular volume, which leads to acti‐
vation of the renin-aldosterone system and may impair renal function. The infusion of intra‐
venous albumin is an important measure to prevent these abnormalities in cirrhotic patients
with tense ascites treated with large-volume or total paracentesis.
Five randomized controlled trials and one prospective study aimed at investigating whether
albumin can be substituted by less expensive plasma expanders (dextran-70,  dextran-40,
Haemaccel 5% and isotonic saline) have recently been reported. It has been observed that total
or repeated large-volume paracentesis associated with intravenous administration of dex‐
tran-70 or Haemaccel is not associated with significant changes in renal and hepatic func‐
tion. The incidence of hyponatremia, renal impairment and hepatic encephalopathy in patients
receiving dextran-70 or Haemaccel was comparable with that in patients receiving albumin.
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In one study, patients treated with dextran-70 showed a significant increase in plasma renin
activity and aldosterone concentration. In a more recent study, however, therapeutic paracent‐
esis plus intravenous dextran-70 administration was not associated with significant changes
in plasma renin activity, which was measured 24 and 96 hours after the treatment. Cabrera et
al., in one study including 14 patients, have suggested that intravenous isotonic saline infu‐
sion can also be a safe and cost effective alternative plasma expander in cirrhotics with tense
ascites treated with paracentesis. Further studies are obviously needed to confirm their find‐
ings. It seems that dextran-40 is not as effective as albumin in preventing renal and electro‐
lyte complications after therapeutic paracentesis, as renal impairment and/or hyponatremia
developed after treatment in a relatively high proportion of patients.
Recently, a multicenter randomized trial comparing therapeutic paracentesis with PVS in
cirrhotic patients with refractory or recurrent ascites has been published. More than 40 pa‐
tients were included in each group. Both treatments were equally effective in mobilizing the
ascites during the first hospital stay, although the duration of hospitalization was signifi‐
cantly longer in the shunt group. There were also no significant differences between both
groups in the number of patients who developed complications or died. The number of re-
admissions for any reason or for ascites, was significantly higher, and the time to first re-
admission for any reason and for ascites significantly shorter in the paracentesis group than
in the shunt group. The total time in hospital during follow-up, however, was similar in the
two groups. The probability of shunt obstruction was 40 % at 1 -year follow-up. The proba‐
bility of survival was similar in both groups. In conclusion, this trial shows that, although
the LeVeen shunt was better than paracentesis in the long-term control of ascites, it did not
reduce the total time in hospital nor prolong survival. On the other hand, patients treated
with PVS required frequent re-operations due to obstruction of the prosthesis. Therapeutic
paracentesis is therefore an alternative treatment to LeVeen shunt in cirrhotic patients with
refractory ascites.
7. Peritoneovenous Shunting
In 1974 LeVeen [19], and colleagues developed a pressure-activated one-way valve for use
in a peritoneovenous shunt (PVS). This device consists of a perforated intra-abdominal tube
connected through a one-way pressure sensitive valve to a silicone tube that traverses the
subcutaneous tissue up to the neck, where it enters one of the jugular veins (usually the in‐
ternal jugular vein). The tip of the intravenous tube is located in the superior vena cava, near
the right atrium or in the right atrium itself. The shunt produces a sustained circulating
blood volume expansion by continuous passage of ascitic fluid to the general circulation.
Flow in the shunt is maintained if there is a 3-5 cm H2O pressure gradient between the ab‐
dominal cavity and the superior vena cava. A loss of this gradient causes the valve to close,
preventing blood from flowing back into the tubing. Two additional shunts have been intro‐
duced Denver and Cordis-Hakim. These latter shunts include a pumping mechanism that
allows flow to be increased or a partially occluded shunt to be cleared.
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The intravenous infusion of ascitic fluid through the shunt is associated with an increase in
circulating blood volume and cardiac output. Since arterial pressure does not rise, there is a
concomitant reduction in peripheral vascular resistance. These hemodynamic changes are
associated with an increase in the plasma concentration of atrial natriuretic factor and a sup‐
pression of plasma levels of renin, aldosterone, noradrenaline and antidiuretic hormone.
Urine volume and free water clearance increase in most patients. However, there is signifi‐
cant natriuresis in less than half of the patients, demonstrating that the PVS does not com‐
pletely correct the abnormal sodium-retaining state associated with cirrhosis. Finally, in
cirrhotic patients with moderate FRF, the PVS may improve renal blood flow and glomeru‐
lar filtration rate. These hemodynamic and hormonal changes persist in most cases and a
significant proportion of patients remains with minimal or no ascites despite a moderate so‐
dium restriction and low diuretic dosage. There are also two studies that suggest that PVS
has a positive effect on the nutritional status of patients in whom the shunt functions for a
prolonged period of time. Despite these positive effects of PVS, there are a large number of
complications, which may occur early in the postoperative period or at any time during fol‐
low-up [19], [20].
The role of PVS in the management of cirrhotic patients with ascitcs is still not well estab‐
lished. Only one prospective study showed that PVS is superior to conventional medical
therapy in the management of ascites and in improving survival. By contrast, four random‐
ized studies have failed to demonstrate a longer survival time in cirrhotic patients with as‐
cites treated with PVS compared with medical therapy. Of these studies, that which was
performed by Stanley et al., 1989 [22], is worth mentioning. They compared PVS with medi‐
cal treatment (diuretics and occasional paracentesis) in 299 patients with cirrhosis and re‐
fractory or recurrent ascites. Although early mortality and probability of survival after
randomization were similar in both therapeutic groups, PVS was more effective in the man‐
agement of ascites than was conventional medical therapy, as indicated by shorter duration
of first hospitalization, longer time to recurrence of ascites, and lower diuretic requirements
during follow-up. However, these results are not surprising, because PVS was compared
with a treatment that by definition was known to be ineffective.
The effect of PVS on survival in patients with FRF has also been studied in a randomized
controlled trial. The treated patients had some improvement in renal function, but their sur‐
vival was unaffected. Several studies have shown that morbidity and survival of cirrhotic
patients treated with PVS correlate with the degree of impairment of liver and renal func‐
tion. Therefore, the best results with this procedure should be expected to occur in those few
patients with diuretic-resistant ascites and preserved hepatic function [23].
7.1. Early complications of peritoneovenous shunting
Acute bacterial infection is the most serious early complication. Staphylococcus aureus is a
frequent isolate and represents the operative contamination of the shunt in some cases. The
prosthesis is usually colonized and the infection cannot be eradicated in most cases unless
the shunt is removed a high mortality can be expected. The prophylactic administration of
anti-staphylococcal antibiotics 24 hours before and 48 hours after surgery reduces the inci‐
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dence of early postoperative infection. Biochemical disseminated intravascular coagulation
(DIC) is seen in practically every cirrhotic patient treated with PVS in the early postopera‐
tive period. Bleeding caused by DIC develops most commonly in those patients with se‐
vere liver disease, but is now very uncommon, because many surgeons remove the ascitic
fluid before inserting the shunt and replace it with normal saline. DIC is thought to devel‐
op because of infusion of factors present in ascitic fluid that activate coagulation (thrombo‐
plastin, activated clotting factors, endotoxin, collagen, plasminogen activator and fibrin split
products). Postoperative fever, probably related to the passage of endotoxin contained in
the ascitic fluid to the general circulation, is almost a constant and disappears spontaneous‐
ly within the second postoperative week. Rapid expansion of the plasma volume is associ‐
ated with a rise in portal pressure and may increase the risk of variceal haemorrhage. This
complication can also be prevented by removing most ascitic fluid before the insertion of
the shunt [24].
7.2. Long-term complications of peritoneovenous shunting
Obstruction of the shunt is the most common complication during follow-up. It occurs in
more than 30% of patients and is usually due to deposition of fibrin within the valve or the
intravenous catheter, thrombotic obstruction of the venous limb of the prosthesis, or throm‐
bosis of the superior vena cava or right atrium initiated at the venous end of the shunt or
damaged endothelium. Shunt obstruction is generally associated with ascites re-accumula‐
tion. Shunt patency can be assessed by Doppler ultrasound or by technetium 99m scintigra‐
phy using intraperitoneal radioisotope injection. If the obstruction is confirmed, a
shuntogram after the injection of contrast into the proximal limb of the shunt may identify
the site of obstruction. Venography or digital angiography is necessary in the case of ob‐
struction of the venous tip of the shunt. Superior vena cava syndrome secondary to total ob‐
struction of the vein and pulmonary embolism are much less common. It is not clear that the
insertion of a titanium tip into the venous end of the LeVeen shunt prevents thrombotic ob‐
struction and the development of superior vena cava thrombosis. Finally, another long-term
complication of PVS is small-bowel obstruction, which occurs in approximately 10% of pa‐
tients and is due to intraperitoneal fibrosis [25].
8. Transjugular intrahepatic portosystemic shunt (TIPS)
The feasibility of intrahepatic portosystemic shunting was first demonstrated by Rosch and
colleagues 1969 in pigs. Colapinto et al; 1982 [27] reported the first application of this techni‐
que to humans. This was attempted following transhepatic obliteration of varices in 20 se‐
verely ill patients with variceal hemorrhage. The authors inflated a balloon catheter in the
intrahepatic track and left it there for 12 hours. In an initial report all six shunts studied
were patent 12 hours after the procedure and one was still patent at autopsy 6 weeks late.
Many demonstrated prolonged patency of the shunt for up to 10 months and ease of recan‐
alizing the radiopaque shunt when occlusion occurred. This expandable stent was then used
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successfully in patients with portal hypertension. Similar good results were soon reported
with the self-expanding Wall stent. Percutaneous portography was used in the early cases to
facilitate transjugular portal vein puncture. With increasing experience this has been re‐
placed by ultrasound guidance in most centers [28].
There is now an increasing array of equipment available for transjugular intrahepatic porto‐
sytemic shunt (TIPS) insertion. The most widely used needles are a standard transjugular bi‐
opsy needle with a straight or reversed bevel (Cook Ltd) or the Richter needle which has a
tapered tip and a blunt obturator (Angiomed, Karlsruhe, Germany). Another set with a
blunt cannula, through which is passed a sharp style is also available (Cook). There is also a
wider choice with regard to the type and dimensions of metal stent. In addition to the origi‐
nal Palmaz and Wall stents, there is the Strecker stent and the Memotherm stent (Angiomed,
Karlsruhe, Germany). Claimed advantages for these new stents are increased radioopacity
(Strecker stent) and improved delivery systems (Memo stent) [29].
A recent randomized controlled study compared the Palmaz and Wall stent in 90 patients
and found little difference in outcome. Early shunt thrombosis was more likely with the
Wall stent (9%), whereas stenosis of the hepatic vein was more likely with the Palmaz stent
(I3%). Experience with the other stents is limited.
As yet the long-term expectations of TIPS have not been fulfilled in those clinical situations
in which long-term efficacy is needed as prevention of variceal rebleeding, ascites, cirrhotic
hydrothorax, Budd-Chiari syndrome, and long-term amelioration of clinical status before
liver transplantation. All these indications need controlled trials against current best optimal
management before TIPS is used routinely even for an individual patient. The high stent ob‐
struction rate is the most important limiting factor, but change in stent shape, coating mate‐
rial or other technical aspects may overcome this [30].
The complications of TIPS are significant if elective and long-term use is considered, thus the
need for trials before new therapies are introduced. In an emergency situation the complica‐
tions due to TIPS are an acceptable risk, but again information from controlled trials is needed.
This is particularly true when TIPS is used as a short-term bridge to liver transplantation.
TIPS will have a place in the treatment of cirrhotic patients. At present short-term rather than
long-term indications appear to be where TIPS will have more beneficial effects [28].
9. Liver transplantation: and hepatic venous obstruction
Liver transplantation for Budd–Chiari syndrome: A European study on 248 patients from 51
centers ) [31]: The results of liver transplantation for Budd–Chiari syndrome (BCS) are poor‐
ly known and the role and timing of the procedure are still controversial. The aim of this
study was to investigate the results of transplantation for BCS, focusing on overall outcome,
on prognostic factors and on the impact of the underlying disease. Methods: An enquiry on
248 patients representing 84% of the patients transplanted for BCS in the European Liver
Transplantation Registry between 1988 and 1999. Results: Of the 248 patients, 70.4% were
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female and 29.6% male. The mean age was 35.7 years. The overall actuarial survival was
76% at 1 year, 71% at 5 years and 68% at 10 years. 77% of deaths occurred in the first 3
months: 47% were due to infection and multiple organ failure, and 18% to graft failure or
hepatic artery thrombosis. Late mortality (>1 year) occurred in nine patients, due to BCS re‐
currence in four of them. The only pre-transplant predictors of mortality on multivariate
analysis (Cox) were impaired renal function and a history of a shunt.
10. Conclusions
Liver transplantation for BCS is an effective treatment, irrespective of the underlying cause,
and should be considered before renal failure occurs [31].
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